Logo

Oncolytics Biotech Signs a Clinical Trial Collaboration with Merck KGaA and Pfizer

Share this

Oncolytics Biotech Signs a Clinical Trial Collaboration with Merck KGaA and Pfizer

Shots:

  • Oncolytics collaborates with Merck KGaA and Pfizer to co-develop Oncolytics’ pelareorep in P-II BRACELET-1 study plus paclitaxel and avelumab. The cost of P-II trial will be shared b/w Pfizer and Oncolytics. Additionally- Oncolytics may exclusively develop pelareorep with Merck and Pfizer during study and post 90 days of interim analysis in HR+/HER2- MBC
  • The P-II BRACELET-1 study (BReast cAnCEr with the Oncolytic Reovirus PeLareorEp in CombinaTion with anti-PD-L1 and Paclitaxel) will involve assessing of paclitaxel as monothx and in combination with pelareorep & avelumab in three cohorts enrolling 45 patients with HR+/HER2- metastatic breast cancer
  • Bavencio (avelumab) is a PD-L1 Ab that blocks the interaction of PD-L1 with PD-1 receptors and is co-developed by Merck KGaA and Pfizer. Pelareorep is an IV administered immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies

Click here to read full press release/ article | Ref: Oncolytics Biotech | Image: Twitter


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions